Prime Medicine, Inc. (PRME) News
Track canonical SquawkNews coverage tagged to PRME, Prime Medicine, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
PRME - Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
PRME - Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 06, 2026, 12:00 PM UTC
L
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease
REGULATION | Jul 23, 2026, 08:05 PM UTC
M
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ: PRME ) from Neutral to Buy and announces $8 price target.
EQUITY | Jun 29, 2026, 10:13 AM UTC
H
PRME: FDA Grants Designation
Prime Medicine says FDA grants regenerative medicine advanced therapy designation to PM359 for treatment of p47phox-deficient CGD
EQUITY | Jun 22, 2026, 12:15 PM UTC
H
PRME Receives FDA RMAT Designation
Prime Medicine receives U.S. FDA Regenerative Medicine Advanced Therapy designation for PM359 to treat Chronic Granulomatous Disease
EQUITY | Jun 22, 2026, 12:01 PM UTC